Pembrolizumab dosing schedule?

What’s the usual pembrolizumab dose?
Pembrolizumab is given at 200 mg by infusion every 3 weeks or 400 mg every 6 weeks. The 200‑mg every‑3‑week option is common because it aligns with standard oncology infusion schedules. Some clinicians use a weight‑based approach—2 mg/kg every 3 weeks or 4 mg/kg every 6 weeks—especially for solid‑tumor indications that benefit from a higher drug exposure. [1]

How does the schedule vary across cancers?
The 200‑/400‑mg regimen works for melanoma, non‑small‑cell lung cancer, head and neck squamous‑cell carcinoma, and urothelial carcinoma, among others. For Hodgkin lymphoma and microsatellite instability‑high solid tumors, the 200‑mg every‑3‑week dose is typical. In rare cases, such as adjuvant therapy for resected melanoma, the 400‑mg every‑6‑week schedule may be chosen to improve convenience without compromising efficacy. [1]

Is dosing different for children?
Pediatric patients receive the same weight‑based dosing (2 mg/kg every 3 weeks or 4 mg/kg every 6 weeks). The pharmacokinetics in children are similar to adults, so no dose adjustment beyond weight is needed unless the child has significant organ impairment. [1]

What if a patient can’t receive a 3‑week infusion?
Switching to the 400‑mg every‑6‑week schedule is an approved alternative. The total drug exposure over a 6‑week period remains comparable, and the FDA labeling allows this switch when clinical circumstances require longer intervals. [1]

How does pembrolizumab’s schedule compare to other checkpoint inhibitors?
Nivolumab is typically dosed at 240 mg every 2 weeks or 480 mg every 4 weeks, while atezolizumab is 1200 mg every 3 weeks. Pembrolizumab’s 3‑ or 6‑week options give a slightly longer interval, which may reduce infusion‑center demand but requires patient adherence to a longer schedule. [1]

When do clinicians decide between 3‑ and 6‑week dosing?
Factors include the patient’s treatment setting (adjuvant vs metastatic), infusion‑center capacity, and potential for missed doses. In outpatient settings with limited infusion slots, the 6‑week schedule can free up resources without changing overall drug exposure. The choice is usually discussed during the initial treatment planning. [1]

What practical steps should pharmacies follow?
Pharmacies reconstitute 200 mg vials into 200‑mL bags for a 3‑week dose or 400 mg into a 400‑mL bag for a 6‑week dose. The infusion lasts 60 minutes for 200 mg and 90 minutes for 400 mg, with pre‑medication for infusion reactions per institutional protocols. Accurate labeling with the correct weight‑based calculation is essential. [1]

Will the dosing schedule change if a patient has organ impairment?
Pembrolizumab has no dose adjustment for renal or hepatic impairment. The standard 200‑ or 400‑mg schedule is maintained regardless of creatinine clearance or liver enzyme levels, though clinicians may monitor for increased toxicity in severely impaired patients. [1]

Can a patient pause treatment or skip a dose?
If a dose is delayed, the next dose can be given within a 4‑week window after the missed infusion without compromising efficacy. If the delay is longer, restarting the 6‑week schedule is recommended. Extended gaps may require dose recalculation to maintain therapeutic levels. [1]

Where can I find the latest dosing guidelines?
The FDA prescribing information and the DrugPatentWatch.com page for pembrolizumab list the approved dosing regimens and any recent label updates. [1]

---

Sources
[1] DrugPatentWatch.com – Pembrolizumab dosing schedule. https://www.drugpatentwatch.com/medicine/pembrolizumab/